Menarini Group and SciClone Pharmaceuticals Announce Exclusive Sub-Licensing Collaboration to Develop and Commercialize ORSERDU® (Elacestrant) in China to Address Advanced or Metastatic Breast Cancer

ORSERDU is the first treatment specifically approved for patients with ER+, HER2- advanced or metastatic breast cancer tumors that harbor ESR1 mutations,...

Related Keywords

Italy ,United States ,France ,China ,Zhao Hong ,Elcin Barker Ergun ,Sciclone Pharmaceuticals Holdings ,Menarini Group ,European Commission ,International Agency For Research On Cancer ,Stemline Therapeutics Inc ,Sciclone Pharmaceuticals Holdings Ltd ,Sciclone Pharmaceuticals Holdings Limited ,Sciclone Pharmaceuticals ,Stemline Therapeutics ,Executive Director ,San Antonio Breast Cancer Symposium ,Safety Information ,Fetal Toxicity ,Clone Pharmaceuticals ,Global Cancer Observatory ,International Agency ,